BYAHConsumer Defensive · Household & Personal Products

BYAH Stock Forecast: Park Ha Biological Technology Co. Ltd. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$2.38

−1.24% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 12 Sept 2026 — in the weakest quartile.

Market cap

$1.9M

Ticker Nerd rank

24 / 100

Median analyst target

—

Analysts covering

—

Total return, dividends reinvested

−9.8%

−33.0%

YTD

−96.3%

−98.7%

From 52W high

−98.8%

From 52W low

+4.8%

$204

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

BYAH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Park Ha Biological Technology Co. Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026

24 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Growth

Revisions

Value

Momentum

Quality

Issuance

Volatility

Size (95): Smaller than most of the companies we track.

Volatility (8): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BYAH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BYAH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BYAH appears on the weeks it earns a place.

Performance

BYAH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Park Ha Biological Technology Co. Ltd. returned −98.7% against +17.5% for the S&P 500, dividends included.

BYAH vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BYAH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Park Ha Biological Technology Co. Ltd. (BYAH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: —
Price / sales: 0.7×
Price / book: 0.3×
EV / EBITDA: 0.8×

Growth & margins

Revenue growth (YoY): 1.5%
Earnings growth (YoY): —
Gross margin: —
Operating margin: −76.5%
Net margin: −214.2%

Returns & dividend

Return on equity: −113.0%
Return on assets: −50.7%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Park Ha Biological Technology Co. Ltd. (BYAH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Park Ha Biological Technology Co. Ltd. has a market value of $1.9M and an enterprise value of −$4.0M.
Shares outstanding: 677,488.
Park Ha Biological Technology Co. Ltd. employs 41 people.

market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

BYAH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHousehold & Personal Products

Company	Market cap	TKN rank
BYAHPark Ha Biological Technology Co. Ltd.	$1.9M	24
TANHTantech Holdings Ltd.	$13.7M	16
ATTTAtlas Trinity Tech Ltd.	$17.4M	9
BIOTInstinct Bio Technical Co. Holdings, Inc.	$1.6M	31
DSYBig Tree Cloud Holdings Ltd.	$31.1M	4
UGUnited-Guardian, Inc.	$32.9M	91
GROVGrove Collaborative Holdings, Inc.	$42.4M	91

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Park Ha Biological Technology Co. Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BYAH news & analysis

PHH, BYAH Deadline: PHH, BYAH Investors with Losses in Excess of $100K Have Opportunity to Lead Park Ha Biological Technology Co., Ltd. Securities Lawsuit

PRNewsWire · 10 Sept 2026negative

Rosen Law Firm is reminding Park Ha Biological Technology Co., Ltd. (BYAH) investors who suffered losses exceeding $100,000 that they have an opportunity to lead a securities lawsuit against the company. The reminder concerns purchasers of BYAH securities.

Why it matters — This indicates ongoing investor litigation against BYAH that could affect the company's legal and financial standing.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Park Ha Biological Technology Co., Ltd. Lawsuit - BYAH

PRNewsWire · 9 Sept 2026negative

Levi & Korsinsky has reminded shareholders of a September 28, 2026 lead plaintiff deadline in a lawsuit against Park Ha Biological Technology Co. Ltd. (BYAH). The lawsuit alleges BYAH structured its IPO with a public float of just 1,200,000 shares (less than 5% of the company), a structure it contends enabled coordinated price manipulation before BYAH shares collapsed 93% in a single session.

Why it matters — BYAH watchers would care because the pending securities lawsuit and the alleged IPO price manipulation could weigh on the company's reputation and expose it to legal and financial risk.

FAQ

Frequently asked questions about BYAH stock

How does Ticker Nerd's model rank BYAH?

As at 12 Sept 2026, Park Ha Biological Technology Co. Ltd. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

What is the BYAH stock forecast for 2030?

No analyst covering Park Ha Biological Technology Co. Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BYAH are extrapolating price history, which says nothing about the business.

How has BYAH stock performed over the past year?

Park Ha Biological Technology Co. Ltd. returned -98.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Park Ha Biological Technology Co. Ltd. do?

Park Ha Biological Technology Co., Ltd. Class A Ordinary Shares represents equity in Park Ha Biological Technology Co., Ltd., a Wuxi-based company focused on skincare and cosmetic products.

What is the latest news on BYAH?

The most recent item we track (PRNewsWire, 10 Sept 2026): "PHH, BYAH Deadline: PHH, BYAH Investors with Losses in Excess of $100K Have Opportunity to Lead Park Ha Biological Technology Co., Ltd. Securities Lawsuit". Rosen Law Firm is reminding Park Ha Biological Technology Co., Ltd. (BYAH) investors who suffered losses exceeding $100,000 that they have an opportunity to lead a securities lawsuit against the company. The reminder concerns purchasers of BYAH securities.

Company

About Park Ha Biological Technology Co. Ltd.

Park Ha Biological Technology Co., Ltd. Class A Ordinary Shares represents equity in Park Ha Biological Technology Co., Ltd., a Wuxi-based company focused on skincare and cosmetic products. The company develops and sells private-label skincare offerings under the Park Ha brand, serving consumers in China through direct product sales and franchise-related channels. Its business also includes franchise services and complementary after-sales beauty services provided through directly operated and franchised locations. Park Ha Biological Technology operates as a holding company with a consumer-focused model centered on personal care and beauty products. The Class A Ordinary Shares provide exposure to a business positioned within the household and personal care segment of the broader consumer market.

CEO Ms. Xiaoqiu Zhang · 41 employees · China · https://parkha.cn